Emerging Cellular Therapies in Hematologic Malignancies

EP: 1.Role of Allogeneic Transplants in Hematologic Malignancies

EP: 2.Hematologic Malignancies and Transplant Options and Conditioning Regimens Used in Allo-HSCT

EP: 3.Supportive Care Measures for Patients Planning to Receive an Allogenic Transplant

EP: 4.Transplant Complications and Survival Outcomes

EP: 5.Clinical Trial Update: CTN Trial

EP: 6.Graft-versus-Host Disease Prophylaxis and Management

EP: 7.Patient Case Studies of GvHD

Now Viewing

EP: 8.Emerging Cellular Therapies in Hematologic Malignancies

EP: 9.Transplant in the Elderly Population

EP: 10.Toxicity Assessment of Precision-Engineered Allo-HSCT

EP: 11.The Role of Allo-HSCT in Higher-Risk MDS

EP: 12.Investigational Allo-HSCT for Advanced Hematologic Malignancies

EP: 13.The Future of Allo-HSCT and Cellular Therapies

EP: 14.OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion

This is a video synopsis/summary of a Peer Exchange featuring Miguel-Angel Perales, MD; Nelli Bejanyan, MD; Amandeep Salhotra, MD; and Arpita Gandhi, MD, MS.

The panel discusses the 2 main directions in allogeneic stem cell transplantation: drug development and graft engineering. Drug development focuses on improving graft-vs-host disease (GVHD) prophylaxis and treatment, while graft engineering explores strategies for T-cell depletion and manipulation.

Graft engineering approaches include improving CD34 selection, using T-cell receptor ⍺/ß depletion, and CD45RA depletion. The ongoing Orca-T trial, which adds regulatory T cells and conventional T cells to a CD34-selected graft, has shown promising results in preventing GVHD.

The panel emphasizes the importance of educating transplant physicians and patients about these advances, with resources like BMT InfoNet providing information on graft manipulation. The National Marrow Donor Program plays a crucial role in facilitating unrelated donor stem cell donation for graft manipulation at central facilities.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.